Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

Market Cap	40.46B -32.0%
Revenue (ttm)	10.91B -70.1%
Net Income	-1.31B
EPS	-0.55
Shares Out	2.39B
PE Ratio	n/a
Forward PE	11.75
Dividend	0.20 (1.18%)
Ex-Dividend Date	n/a

Volume	14,372,370
Average Volume	34,396,176
Open	17.14
Previous Close	17.07
Day's Range	16.90 - 17.20
52-Week Range	16.75 - 27.80
Beta	0.66
RSI	38.34
Earnings Date	Apr 28, 2026

About SHE:300122

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7,220
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300122

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.